![logo](/logos/ATH.AX.webp)
Alterity Therapeutics Limited
ASX:ATH.AX
0 (AUD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alterity Therapeutics Limited |
Symbool | ATH.AX |
Munteenheid | AUD |
Prijs | 0.003 |
Beurswaarde | 18,621,176 |
Dividendpercentage | 0% |
52-weken bereik | 0.003 - 0.009 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Geoffrey Paul Kempler B.Sc, B.Sc. |
Website | https://alteritytherapeutics.com |
An error occurred while fetching data.
Over Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)